Therapeutic Development Programs
As a company, we have optimized and refined a proven platform to address and execute across multiple markets – advancing products indicated for both medically-prescribed hospital-based use as well as non-prescription consumer care.
Our products in development address highly prevalent medical conditions in the fields of dermatology, hospital-acquired infection, and oncology.
Our novel, Matrix3 triple synergy formula provides faster onset and improved efficacy against drug-resistant bacteria including MRSA and Pseudomonas.
Our Hospital Infections program is advancing an injectable product for Drug-Resistant Enterococcus (“VRE”) – a life-threatening hospital-acquired infection.
Andira uses the most translational research techniques available to optimize treatments to address Metastatic Breast Cancer.